Personalis, Inc. (PSNL)
- Previous Close
1.2500 - Open
1.2604 - Bid 1.2500 x 400
- Ask 1.3000 x 100
- Day's Range
1.2500 - 1.2800 - 52 Week Range
0.8910 - 2.6000 - Volume
48,957 - Avg. Volume
331,317 - Market Cap (intraday)
64.78M - Beta (5Y Monthly) 1.95
- PE Ratio (TTM)
-- - EPS (TTM)
-2.2500 - Earnings Date May 8, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
4.75
Personalis, Inc. develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD) and recurrence in cancer; and ImmunoID NeXT, a tissue-based test that combines whole exome (DNA) and whole transcriptome (RNA) sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for detection of MRD and recurrence in cancer; and NeXT Dx, a comprehensive tumor profiling test that unlocks the entire exome (DNA) and transcriptome (RNA) with matched tumor-normal analysis. In addition, the company performs whole exome sequencing (WES) of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing (WGS) on human samples for research projects, such as population sequencing initiatives, as well as offers sequencing and data analysis services to support population sequencing initiatives. Its customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and patients. The company was incorporated in 2011 and is headquartered in Fremont, California.
www.personalis.com223
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: PSNL
Performance Overview: PSNL
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PSNL
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PSNL
Valuation Measures
Market Cap
64.78M
Enterprise Value
-1.67M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.83
Price/Book (mrq)
0.50
Enterprise Value/Revenue
-0.02
Enterprise Value/EBITDA
0.02
Financial Highlights
Profitability and Income Statement
Profit Margin
-147.38%
Return on Assets (ttm)
-23.25%
Return on Equity (ttm)
-62.31%
Revenue (ttm)
73.48M
Net Income Avi to Common (ttm)
-108.3M
Diluted EPS (ttm)
-2.2500
Balance Sheet and Cash Flow
Total Cash (mrq)
114.18M
Total Debt/Equity (mrq)
37.83%
Levered Free Cash Flow (ttm)
-34.04M